These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11257413)

  • 1. The bare skin and the nose as non-invasive routes for administering peptide vaccines.
    Partidos CD; Beignon AS; Semetey V; Briand JP; Muller S
    Vaccine; 2001 Mar; 19(17-19):2708-15. PubMed ID: 11257413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy.
    Gupta N; Vedi S; Kunimoto DY; Agrawal B; Kumar R
    Vaccine; 2016 Nov; 34(46):5677-5688. PubMed ID: 27693020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routing dependent immune responses after experimental R848-adjuvated vaccination.
    van Aalst S; Jansen MAA; Ludwig IS; van der Zee R; van Eden W; Broere F
    Vaccine; 2018 Mar; 36(11):1405-1413. PubMed ID: 29409680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.
    Nevagi RJ; Khalil ZG; Hussein WM; Powell J; Batzloff MR; Capon RJ; Good MF; Skwarczynski M; Toth I
    Acta Biomater; 2018 Oct; 80():278-287. PubMed ID: 30266637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.
    Ninomiya A; Ogasawara K; Kajino K; Takada A; Kida H
    Vaccine; 2002 Aug; 20(25-26):3123-9. PubMed ID: 12163263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal immunization with novel EspA-Tir-M fusion protein induces protective immunity against enterohemorrhagic Escherichia coli O157:H7 challenge in mice.
    Lin R; Zhu B; Zhang Y; Bai Y; Zhi F; Long B; Li Y; Wu Y; Wu X; Fan H
    Microb Pathog; 2017 Apr; 105():19-24. PubMed ID: 28163157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RGD motif enhances immunogenicity and adjuvanicity of peptide antigens following intranasal immunization.
    Yano A; Onozuka A; Matin K; Imai S; Hanada N; Nisizawa T
    Vaccine; 2003 Dec; 22(2):237-43. PubMed ID: 14615151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity.
    Mizuno D; Kimoto T; Takei T; Fukuta A; Shinahara W; Takahashi E; Yano M; Kido H
    Vaccine; 2011 Jul; 29(33):5368-78. PubMed ID: 21669246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres.
    Brandhonneur N; Loizel C; Chevanne F; Wakeley P; Jestin A; Le Potier MF; Le Corre P
    Int J Pharm; 2009 May; 373(1-2):16-23. PubMed ID: 19429284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice.
    Przetak M; Chow J; Cheng H; Rose J; Hawkins LD; Ishizaka ST
    Vaccine; 2003 Feb; 21(9-10):961-70. PubMed ID: 12547609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
    Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
    J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of vaccine peptides by rapid conjugation to baculovirus particles.
    Wilson S; Baird M; Ward VK
    Vaccine; 2008 May; 26(20):2451-6. PubMed ID: 18417258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple antigen peptide consisting of B- and T-cell epitopes of F1 antigen of Y. pestis showed enhanced humoral and mucosal immune response in different strains of mice.
    Ali R; Kumar S; Naqvi RA; Sheikh IA; Rao DN
    Int Immunopharmacol; 2013 Jan; 15(1):97-105. PubMed ID: 23174507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying peptide antigens onto bare skin: induction of humoral and cellular immune responses and potential for vaccination.
    Partidos CD; Beignon AS; Brown F; Kramer E; Briand JP; Muller S
    J Control Release; 2002 Dec; 85(1-3):27-34. PubMed ID: 12480308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel method for enhancement of peptide vaccination utilizing T-cell epitopes from conventional vaccines.
    Yano A; Miwa Y; Kanazawa Y; Ito K; Makino M; Imai S; Hanada N; Nisizawa T
    Vaccine; 2013 Mar; 31(11):1510-5. PubMed ID: 23318151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel antigen-carrier system: the Mycobacterium tuberculosis Acr protein carried by raw starch microparticles.
    Moreno-Mendieta SA; Guillén D; Espitia C; Hernández-Pando R; Sanchez S; Rodríguez-Sanoja R
    Int J Pharm; 2014 Oct; 474(1-2):241-8. PubMed ID: 25093695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV-1.
    Kabiri M; Sankian M; Hosseinpour M; Tafaghodi M
    Int J Pharm; 2018 Oct; 549(1-2):404-414. PubMed ID: 30075250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New routes of administration: epidermal, transcutaneous mucosal ways of vaccination].
    Denis F; Alain S; Ploy MC
    Med Sci (Paris); 2007 Apr; 23(4):379-85. PubMed ID: 17433227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.